FDA Refuses To File Translarna NDA; PTC Plummets
This article was originally published in Scrip
Just as things looked like they couldn't get any worse for the Duchenne muscular dystrophy (DMD) research and development community – and for patients – PTC Therapeutics Inc. revealed it had received a refuse-to-file (RTF) letter from the FDA for the firm's new drug application (NDA) for Translarna (ataluren).
You may also be interested in...
PTC Tumbles On Ataluren Failure In Cystic Fibrosis
With a second Phase III failure in nonsense mutation CF, the New Jersey biotech ends development of ataluren for CF, but continues with the drug in three smaller indications.
DMD Pipeline: After Sarepta’s First-Ever Approval, Are Combinations Next?
Several companies have DMD drug candidates waiting in the wings to follow Sarepta’s Exondys 51 into the commercial market after FDA approval of the exon-skipping therapy, which could be the backbone for future combination treatment regimens.
Sarepta Must Balance Exondys 51 Confirmatory Trials And Sales
How will the confirmatory trial necessary to convert accelerated approval to full approval affect sales given the small size of the target population?